Working languages:
Korean to English
English to Korean

young jang
Biotech and clinical protocol, MBA

Uiwang-si, Kyonggi-do, South Korea
Local time: 03:10 KST (GMT+9)

Native in: Korean Native in Korean
  • Send message through ProZ.com
Feedback from
clients and colleagues

on Willingness to Work Again info
No feedback collected
Account type Freelance translator and/or interpreter, Identity Verified Verified site user
Data security Created by Evelio Clavel-Rosales This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliations This person is not affiliated with any business or Blue Board record at ProZ.com.
Services Translation, Editing/proofreading, Website localization
Expertise
Specializes in:
BotanyMedical (general)
AgricultureEnvironment & Ecology
Food & DrinkBusiness/Commerce (general)
Engineering (general)Medical: Health Care
Medical: Pharmaceuticals
Portfolio Sample translations submitted: 1
Korean to English: Biotechnology, PROTOCOLS
Source text - Korean
Korea (한국어)
Translation - English
English

Translation education Master's degree - Pennsylvania State University
Experience Years of experience: 7. Registered at ProZ.com: Jul 2016.
ProZ.com Certified PRO certificate(s) N/A
Credentials N/A
Memberships N/A
Software Adobe Acrobat, Microsoft Excel, Microsoft Office Pro, Microsoft Word, Powerpoint, Wordfast
Bio

 A freelance English to Korean/Korean to English translator specializing in the fields of Medical, Environment, Chemical engineering, Food technology, Cosmetics etc. 


Available Programs: Wordfast, Trados, Smartcat, Memsource.

 

Translation and Proofreading experience: 5 years.

 

<Clinical Protocols, ICF, IB, etc. >

 

-A 1-year double-blind, triple-dummy, active comparator-controlled study evaluating tofacitinib 5 mg BID with and without MTX and adalimumab 40 mg subcutaneously every other week with MTX.

-A Combined Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Induction and Maintenance Study Evaluating the Safety and Efficacy of GS-5745 in Subjects with Moderately to Severely Active Ulcerative Colitis

-A multicenter, double-blind, placebo-controlled, randomized phase 3 trial with 1 planned IA, comparing gilteritinib as maintenance therapy versus placebo, in FLT3/ITD AML subjects in CR1.

-Comparable clinical efficacy, safety and immunogenicity of infliximab biosimilar (CT-P13) after transition from reference infliximab (Remicade®) in children with established inflammatory bowel disease: a multi-centre prospective observational

-A phase 1, first-in-human (FIH), open-label, multicenter, dose-escalation study of the safety, tolerability, activity and PK of REGN3767 administered as monotherapy and in combination with REGN2810 in patients with advanced malignancies.

-A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

-Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ertugliflozin Monotherapy in Subjects with Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003/B1521022)

-Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ertugliflozin in Subjects with Type 2 Diabetes Mellitus and Inadequate Glycemic Control with Sitagliptin and Metformin (Study MK 8835-006/B1521015)

-Randomized Double-blind Factorial Study to Evaluate the Efficacy and Safety of the Combination of Ertugliflozin and Sitagliptin Compared with Ertugliflozin Alone and Sitagliptin Alone in Subjects with Type 2 Diabetes Mellitus and Inadequate Glycemic Control with Metformin Monotherapy (MK-8835-005/B1521019)

-Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of the Combination of Ertugliflozin and Sitagliptin in Subjects with Type 2 Diabetes Mellitus and Inadequate Glycemic Control with Diet and Exercise (MK-8835-017/B1521047)

-Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Efficacy and Safety of Addition of Ertugliflozin, Compared with Addition of Glimepiride, in Subjects with Type 2 Diabetes Mellitus and Inadequate Glycemic Control with Metformin (MK-8835-002/B1521013)

-Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ertugliflozin in Subjects with Type 2 Diabetes Mellitus, Stage 3 Chronic Kidney Disease, and Inadequate Glycemic Control with Background Antihyperglycemic Therapy (MK-8835-001/B1521016)

-A Phase 2, Open Label, 2 Arm, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration Resistant Prostate Cancer Who Previously Received Taxane Based Chemotherapy and Progressed on at Least 1 Novel Hormonal -Agent (Enzalutamide and/or Abiraterone Acetate/Prednisone)

-A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies

-A randomized, placebo-controlled, single-blind single-ascending dose (SAD) phase in healthy subjects

-An open-label, multiple-ascending dose (MAD) phase in patients with moderate to severe hemophilia A or B without inhibitors

-An open-label, exploratory multiple dose (MD) phase in patients with moderate to severe hemophilia A or B without inhibitors

-An open-label MD phase in patients with moderate to severe hemophilia A or B with inhibitors

-A Phase 1/2 multicenter, multinational, 537open-label extension study to evaluate the long-term safety and efficacy of fitusiran in male patients with moderate or severe hemophilia A or B, with or without inhibitors, who previously tolerated dosing in Study ALN AT3SC 001

-A Randomized, Open-Label, Phase 3 Study to Assess the Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients with X- linked Hypophosphatemia (XLH)

-A PHASE I, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ESCALATING DOSES OF DHES0815A IN PATIENTS WITH HER2 POSITIVE BREAST CANCER

-A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study with Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults with X-linked Hypophosphatemia (XLH)

-A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of MYL-1402O Compared with Avastin®, in the First-line Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

-An Exploratory Tumor Biopsy-Driven Study To Understand The Relationship Between Biomarkers and Indicators of Clinical Response in Immunomodulatory Treatment-Naïve Unresectable Stage III/IV Melanoma Patients Receiving REGN2810 (Anti-PD-1)

-etc.



< Company info documents >


- Biocore. Co. Product information document (KE)

- JW Holdings. Product development strategy (KE)

- Meditox Co. Botulinum product information document (KE)

-LG Lifescience. Medical device information document (Elavie Injection) (KE)

-ConvaTech U.S. Customer information document (KE)

-Pangen Biotech. Material Specification Sheet (KE)

-California Almond Brochure (EK)

-IOPcorporate Medical Device Manual(E K)

-Valeo Inc. Antitrust Compliance (E K)

-Corestem Standard Operation Process for Biological procedures (KE)

-Washington Department of Health Code of Conduct(E K)

-Molina Healthcare ‘Medicare and Medicaid’ Brochure(E K)

-Advanced Instrument, ‘Anoxomat-III’ User Guide(E K)

-Neulasta ‘On body’ Brochure(E K)

-Company info clip subtitle (EK), (E K)

-Exoplan implant product(E K)

-MicroVention Occulsion Balloon Catheter Brochure(E K)

-Hysteroscopic tissue removal system(E K)

-Instruction leaflet for SAVARA PHARMACEUTICALS Study(E K)

- U.S. Department of Health and Human Services, Notice of Health Information Practices(E K)

-3M Form dressing Manual(E K)

-3M Critical and Chronic Care Solutions Division Introduction(E K)

-Bristol-Myers Squibb ICF(E K)

-Alianz insurance info(E K)

-BBC Inc. Formats Delivery Specifications Contract (E K)

-Fairfax vote info (E K)

-KB stocks (KE)

-DLM Co., Ltd, Company info (KE)

-Keumho environment Co., Ltd, Company info (KE)

-FDA Import Operation Manual (E K)

-etc.

 

 

< Research articles >

 

- Science, Technology & Innovation Policy Report (STEPI) (EK)
- Key Trends in CO2 Emissions thesis (E
K)
- Regulatory Impact Analysis for the Proposed Standards of Performance for Greenhouse Gas Emissions for New Stationary Sources: Electric Utility Generating Units (U.S. EPA) (E
K)
- Synthesis report on the aggregate effect of the intended nationally determined contributions(UN) (E
K)
- Modeling the flows of engineered nanomaterials during waste handling Article (E
K)
- The Korean Society of Anesthesiologists Homepage (K
E)

- VDT (Video Display Terminal) thesis (KE)

- The correlation between stress levels and the actual consumption of sugar in female university students article (KE)

- Biological and genetic characteristics of multidrug-resistant Enterobacter cloacae (KE)

- Study on the field application of the analysis method for pesticide residues in ginseng (KE)

- etc.

Keywords: English, Korean, Bio, Biotechnology, Medicine, clinical, trial, ICF, Pharmacology, Environment, Food


Profile last updated
Mar 6, 2019



More translators and interpreters: Korean to English - English to Korean   More language pairs



Your current localization setting

English

Select a language

All of ProZ.com
  • All of ProZ.com
  • Term search
  • Jobs
  • Forums
  • Multiple search